Yesterday I dropped something that moved faster than I expected, and the reactions ended up being just as telling as the data itself. An Eli Lilly funded scientist is set to present rodent data at the American Diabetes Association meeting on a quintuple agonist, a five pathway compound that has already edged out Retatrutide in rat weight loss. Retatrutide has been treated as the ceiling by a lot of people in this space, so even early animal data suggesting something may surpass it forces a...

Originally posted on obesity.news on March 5th, 2026 Something very exciting was announced today that may not look extremely dramatic on the surface but could end up reshaping how millions of Americans access obesity treatment. Affordably. Eli Lilly announced the launch of Lilly Employer Connect , a platform designed to help employers offer obesity treatment coverage for their employees, including Zepbound. Early headlines have focused on a single number. $449 for Zepbound. But it’s...

Originally posted on obesity.news on March 9th, 2026 UPDATED 3/10/26: Patient eligibility requirements have been outlined and can be found at the bottom of this article. The question I have been hearing repeatedly since early January is straightforward. Will Medicare actually start covering GLP-1 medications this summer? New documents from the Centers for Medicare & Medicaid Services, along with a statement from Eli Lilly, suggest that something meaningful could begin in July of 2026, but it...